#United States #Amgen #Thousand Oaks #Tezspire® #CRSwNP

Positive Outcomes in Chronic Rhinosinusitis Treatment with Tezspire®

The recently concluded Phase 3 WAYPOINT trial demonstrated the efficacy of Tezspire® (tezepelumab-ekko) in treating chronic rhinosinusitis with nasal polyps (CRSwNP). Conducted by Amgen and AstraZeneca, the trial provided substantial evidence of significant improvements in patient symptoms, underscoring the potential of this therapy.

Key Findings of the WAYPOINT Trial

The WAYPOINT trial results, published in the New England Journal of Medicine and presented at the AAAAI/WAO Congress 2025, revealed that Tezspire® drastically reduced both the severity of nasal polyps and nasal congestion in patients. Specifically, it recorded a notable improvement in nasal polyp severity, measured by the Nasal Polyp Score (NPS), which showed a decrease of -2.065 (p<0.0001) compared to placebo. This change represents a significant milestone for patients who regularly face the challenges posed by CRSwNP.

The trial participants also reported substantial reductions in their nasal congestion levels, demonstrating a decrease of -1.028 (p<0.0001) in the Nasal Congestion Score (NCS). Remarkably, improvements were already noticeable as early as two weeks and four weeks after treatment initiation, highlighting the rapid onset of action for Tezspire®.

Dr. Jay Bradner from Amgen emphasized the significance of these findings, stating,